Invesco Biotechnology & Genome ETF (PBE) — ()
Key Metrics
News
2 ETFs to Watch for Outsized Volume on Biotechnology Stocks
Published: by:
Sentiment: Positive ()
Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.
Read More
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Published: by:
Sentiment: Neutral ()
Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
Read More
About Invesco Biotechnology & Genome ETF PBE
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.